| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERM.10.53 |
| P698 | PubMed publication ID | 20629511 |
| P2093 | author name string | Peter S Nelson | |
| Christopher R Porter | |||
| Daniel J Lewinshtein | |||
| P2860 | cites work | Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer | Q40401118 |
| Report of the consensus workshop on screening and global strategy for prostate cancer | Q40589607 | ||
| A critical and comparative study of methods of isolating tumour cells from the blood | Q41216670 | ||
| Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis | Q41778982 | ||
| Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-captur | Q42047685 | ||
| TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy | Q42145160 | ||
| Observer variability in the histopathological reporting of needle biopsy specimens of the prostate | Q42439831 | ||
| Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer | Q42654001 | ||
| Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. | Q42760416 | ||
| Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer | Q43614751 | ||
| Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling | Q43800223 | ||
| The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. | Q43824461 | ||
| Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial | Q44037457 | ||
| Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. | Q44324289 | ||
| Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. | Q44686949 | ||
| Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study | Q45018220 | ||
| Hepsin promotes prostate cancer progression and metastasis | Q45026829 | ||
| Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. | Q45878104 | ||
| Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy | Q46522673 | ||
| Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study | Q46616101 | ||
| Influence of number of CAG repeats on local control in the RTOG 86-10 protocol | Q46931181 | ||
| Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. | Q46972239 | ||
| PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer | Q47919199 | ||
| A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer | Q48030260 | ||
| A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis | Q48081174 | ||
| Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. | Q51596197 | ||
| Analysis of CDKN1C in Beckwith Wiedemann syndrome. | Q52539681 | ||
| Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. | Q52941765 | ||
| CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. | Q53324496 | ||
| Chromosome translocations: dangerous liaisons revisited. | Q53391539 | ||
| Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. | Q54438321 | ||
| Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome. | Q54487746 | ||
| Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. | Q54539077 | ||
| TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. | Q54571377 | ||
| Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition | Q56906348 | ||
| ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER | Q57274821 | ||
| Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome | Q57790493 | ||
| Gene ontology: tool for the unification of biology | Q23781406 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 | ||
| Mortality results from a randomized prostate-cancer screening trial | Q24601536 | ||
| Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes | Q24673023 | ||
| Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement | Q24676201 | ||
| Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. | Q27824849 | ||
| FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. | Q27851411 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| MicroRNAs: small RNAs with a big role in gene regulation | Q27860896 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| CpG-rich islands and the function of DNA methylation | Q28131800 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor | Q28215563 | ||
| Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
| Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway | Q28382812 | ||
| Disruption of the COP9 signalosome Csn2 subunit in mice causes deficient cell proliferation, accumulation of p53 and cyclin E, and early embryonic death | Q28588169 | ||
| Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity | Q28766934 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 | ||
| The development of androgen-independent prostate cancer | Q29615650 | ||
| High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays | Q29615979 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes | Q29617061 | ||
| Screening and prostate-cancer mortality in a randomized European study | Q29617485 | ||
| Delineation of prognostic biomarkers in prostate cancer | Q29617971 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer | Q30080026 | ||
| PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. | Q30472730 | ||
| Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients | Q31127144 | ||
| Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. | Q31151905 | ||
| Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis | Q33266259 | ||
| Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy | Q33361134 | ||
| A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy | Q33375063 | ||
| Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 | ||
| Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage | Q33696238 | ||
| Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer | Q33716657 | ||
| Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer | Q33723651 | ||
| A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer | Q33787023 | ||
| Management of advanced prostate cancer | Q33856417 | ||
| Phenotypic analysis of mice lacking the Tmprss2-encoded protease | Q34302430 | ||
| Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors | Q34320113 | ||
| The androgen receptor gene and its influence on the development and progression of prostate cancer | Q34395691 | ||
| Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death | Q34424612 | ||
| Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer | Q34435524 | ||
| TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer | Q34508696 | ||
| Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer | Q34596148 | ||
| Genomic strategy for targeting therapy in castration-resistant prostate cancer | Q34605452 | ||
| Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer | Q34613941 | ||
| Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. | Q34732738 | ||
| Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer | Q34751456 | ||
| Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 | ||
| Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. | Q34798892 | ||
| Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer | Q34803786 | ||
| Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. | Q34973214 | ||
| Biological response to radiation therapy | Q35151872 | ||
| Gene expression profiling identifies clinically relevant subtypes of prostate cancer | Q35554359 | ||
| Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease | Q35640625 | ||
| Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy | Q35751889 | ||
| Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis | Q35933390 | ||
| Molecular biomarker in prostate cancer: the role of CpG island hypermethylation | Q35952789 | ||
| Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005 | Q36011880 | ||
| Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis | Q36309725 | ||
| Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 | ||
| PTEN function in normal and neoplastic growth | Q36368011 | ||
| Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer | Q36481328 | ||
| Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer | Q36610777 | ||
| Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline | Q36778558 | ||
| Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer | Q36785930 | ||
| Abnormal DNA methylation, epigenetics, and prostate cancer | Q36813979 | ||
| Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy | Q36888299 | ||
| Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer | Q36952071 | ||
| Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy | Q37016855 | ||
| Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer | Q37024519 | ||
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet | Q37163550 | ||
| Recurrent gene fusions in prostate cancer | Q37194503 | ||
| CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer | Q37243155 | ||
| HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Q37325230 | ||
| Epigenetic alterations in human prostate cancers. | Q37328845 | ||
| MicroRNAs and cancer: current state and future perspectives in urologic oncology | Q37360740 | ||
| Predictive models in external beam radiotherapy for clinically localized prostate cancer | Q37526758 | ||
| Predictive models of toxicity in external radiotherapy: dosimetric issues. | Q37526771 | ||
| Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues | Q37526775 | ||
| Biomolecular markers of outcome prediction in prostate cancer. | Q37526794 | ||
| Triple-negative breast cancer--current status and future directions | Q37630082 | ||
| Widespread deregulation of microRNA expression in human prostate cancer. | Q38297946 | ||
| Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells | Q38352246 | ||
| Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate | Q39506775 | ||
| Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens | Q39571552 | ||
| Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer | Q39787898 | ||
| To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. | Q39884923 | ||
| TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. | Q39976204 | ||
| Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer | Q40099013 | ||
| MicroRNA expression profiling in prostate cancer | Q40110318 | ||
| Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer | Q40236516 | ||
| Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias | Q40293372 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 619-636 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare | Q15756305 |
| P1476 | title | Genomic predictors of prostate cancer therapy outcomes | |
| P478 | volume | 10 |
Search more.